Treatment experience of overactive bladder: clinical cases

Treatment experience of overactive bladder: clinical cases

R.V. Salyukov^1,2, Yu.R. Salyukova³, M.V. Frolova⁴

¹RUDN University, Moscow

²Rehabilitation Center for Disabled People «Preodolenie», Moscow

³Russian Scientific Center of Roentgenoradiology, Moscow

⁴Lomonosov Moscow State University, Moscow

Overactive bladder (OAB) is a common syndrome accompanied by a number of lower urinary tract symptoms. The first line of medical therapy for OAB is medicines belonging to the group of m-cholinolytics. Medicines of this group are not safe, as they can penetrate the blood-brain barrier and affect cognitive functions, which is especially important in light of the fact that OAB is more common in elderly patients. Fesoterodine is the only drug from m-cholinolytics group that is classified as class B according to the FORTA classification for safety and efficacy. The article presents descriptions of several clinical cases with OAB that differ in the etiology and course, comorbid background, gender and age of patients. In all cases it was possible to achieve a stable positive effect with fesoterodine. Fesoterodine can be used in patients with dysuric disorders after transurethral resection of the prostate, benign prostatic hyperplasia, in the inefficacy of another cholinolytic, and in idiopathic and neurogenic OAB. Autonomic dysreflexia may be a new promising indication for fesoterodine use, but this statement requires further research.

Keywords: fesoterodine, overactive bladder, benign prostatic hyperplasia, neurogenic lower urinary tract dysfunction, autonomic dysreflexia.

For citation: Salyukov R.V., Salyukova Yu.R., Frolova M.V. Treatment experience of overactive bladder: clinical cases. RMJ. 2020;13:14–18.